Fig. 7From: Mediation of PKM2-dependent glycolytic and non-glycolytic pathways by ENO2 in head and neck cancer developmentAP-III-a4 induces remission of head and neck tumors in xenograft mice. a Effect of AP-III-a4 treatment on tumor growth measured by tumor volume at the indicated time points. Six-week-old nude mice with subcutaneously implanted UM-1 cells were randomized into two groups to receive vehicle (PBS) or AP-III-a4 treatment for 28 days. b Images of xenograft tumors of each group at the same time of study end. c Tumor weight measured at the end of the treatment. d Mouse body weight recorded every four days during the treatment process. e Histology of major organs from mice receiving vehicle or AP-III-a4 treatment. f Immunostaining of Ki67, PKM2, p-ERK and p-AKT in tumor xenografts from mice receiving vehicle or AP-III-a4 treatment. Representative IHC images and quantitative data are shown in the left and right panels, respectively. Scale bar depicts 2mm. *p<0.05; **p<0.01Back to article page